Skip to main content
ACRS
NASDAQ Life Sciences

Aclaris Therapeutics Unveils Strong Clinical Pipeline Progress and Extended Cash Runway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.64
Mkt Cap
$290.365M
52W Low
$1.05
52W High
$3.475
52W Position info
151% above low
Off High info
24% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

ACRS has more than doubled off its 52-week low of $1.05 on light trading volume (0.4× avg).

Summary

Aclaris Therapeutics provided a comprehensive corporate overview, highlighting positive interim clinical data for ATI-052 and ATI-2138, outlining multiple upcoming clinical milestones in 2026 and 2027, and confirming a cash runway into the second half of 2028.


Key Events · Product Development and Regulatory · ACRS

  • Positive ATI-052 Phase 1a Interim Results

    Interim data for the bispecific antibody ATI-052 exceeded expectations, showing favorable tolerability, strong pharmacokinetics supporting potential 3-month dosing, and robust pharmacodynamic responses.

  • Strong ATI-2138 Phase 2a Atopic Dermatitis Data

    The Phase 2a trial for the ITK/JAK3 inhibitor ATI-2138 demonstrated favorable safety and efficacy comparable to approved drugs for atopic dermatitis, with significant itch relief and improvements in disease severity.

  • Multiple Clinical Milestones Ahead

    The company anticipates several inflection points in 2026 and 2027 across its Bosakitug, ATI-052, ATI-2138, and next-generation programs, including new trial initiations and top-line results.

  • Extended Cash Runway

    Aclaris Therapeutics reported cash, cash equivalents, and marketable securities of $167 million as of Q3 2025, extending its cash runway into the second half of 2028.


Analysis · ACRS · Life Sciences

This 8-K filing, through its corporate overview presentation, delivers a highly positive update on Aclaris Therapeutics' entire clinical pipeline. The interim Phase 1a results for ATI-052 exceeded expectations, demonstrating favorable tolerability, a strong pharmacokinetic profile supporting potential extended dosing, and robust pharmacodynamic responses. Similarly, the Phase 2a trial for ATI-2138 showed favorable safety and efficacy comparable to approved drugs for atopic dermatitis, with significant itch relief. The company has a clear roadmap with several anticipated clinical inflection points in 2026 and 2027 for its Bosakitug, ATI-052, and ATI-2138 programs, as well as next-generation therapeutics. Furthermore, the confirmed cash runway into the second half of 2028 provides financial stability, significantly de-risking the company and supporting its ambitious development plans. These updates collectively present a strong positive outlook for the company's future.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ACRS was trading at $2.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $290.4M. The 52-week trading range was $1.05 to $3.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACRS - Latest Insights

ACRS
Nov 05, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.61
Real-time Price: $3.86 info
Change: +$0.250 (+7%) info
Market Cap: $618.587M info
ACRS
Nov 05, 2026, 7:15 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.61
Real-time Price: $3.86 info
Change: +$0.250 (+7%) info
Market Cap: $618.587M info
ACRS
Oct 27, 2026, 5:15 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.72
Real-time Price: $3.86 info
Change: +$0.140 (+4%) info
Market Cap: $618.587M info
ACRS
Oct 27, 2026, 6:43 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.63
Real-time Price: $3.86 info
Change: +$0.230 (+6%) info
Market Cap: $618.587M info
ACRS
Oct 27, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.03
Real-time Price: $3.86 info
Change: -$0.170 (-4%) info
Market Cap: $618.587M info